Turncliff RZ[au] - Search Results

Year	Number of Results
2000	3
2001	1
2003	1
2004	2
2005	1
2006	3
2007	1
2009	1
2011	1
2012	1
2017	1
2023	0

1

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.

Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L. Hard ML, et al. Among authors: turncliff rz. J Clin Psychopharmacol. 2017 Jun;37(3):289-295. doi: 10.1097/JCP.0000000000000691. J Clin Psychopharmacol. 2017. PMID: 28350572 Free PMC article.

2

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.

Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC. Dunbar JL, et al. Among authors: turncliff rz. Alcohol Clin Exp Res. 2006 Mar;30(3):480-90. doi: 10.1111/j.1530-0277.2006.00052.x. Alcohol Clin Exp Res. 2006. PMID: 16499489 Clinical Trial.

3

P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes.

Annaert PP, Turncliff RZ, Booth CL, Thakker DR, Brouwer KL. Annaert PP, et al. Among authors: turncliff rz. Drug Metab Dispos. 2001 Oct;29(10):1277-83. Drug Metab Dispos. 2001. PMID: 11560870

4

Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence.

Dunbar JL, Turncliff RZ, Hayes SC, Farrell CB. Dunbar JL, et al. Among authors: turncliff rz. J Stud Alcohol Drugs. 2007 Nov;68(6):862-70. doi: 10.15288/jsad.2007.68.862. J Stud Alcohol Drugs. 2007. PMID: 17960304

5

Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes.

Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, Brouwer KL. Turncliff RZ, et al. J Pharmacol Exp Ther. 2006 Aug;318(2):881-9. doi: 10.1124/jpet.106.102616. Epub 2006 May 11. J Pharmacol Exp Ther. 2006. PMID: 16690724 Free article.

6

Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver.

Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL. Zamek-Gliszczynski MJ, et al. Among authors: turncliff rz. J Pharmacol Exp Ther. 2003 Feb;304(2):801-9. doi: 10.1124/jpet.102.044107. J Pharmacol Exp Ther. 2003. PMID: 12538836

7

Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.

Turncliff RZ, Dunbar JL, Dong Q, Silverman BL, Ehrich EW, Dilzer SC, Lasseter KC. Turncliff RZ, et al. J Clin Pharmacol. 2005 Nov;45(11):1259-67. doi: 10.1177/0091270005280199. J Clin Pharmacol. 2005. PMID: 16239359 Clinical Trial.

8

The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.

Everson G, Lasseter KC, Anderson KE, Bauer LA, Carithens RL Jr, Wilner KD, Johnson A, Anziano RJ, Smolarek TA, Turncliff RZ. Everson G, et al. Among authors: turncliff rz. Br J Clin Pharmacol. 2000;49 Suppl 1(Suppl 1):21S-26S. doi: 10.1046/j.1365-2125.2000.00149.x. Br J Clin Pharmacol. 2000. PMID: 10771450 Free PMC article. Clinical Trial.

9

Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats.

Todtenkopf MS, O'Neill KS, Kriksciukaite K, Turncliff RZ, Dean RL, Ostrovsky-Day I, Deaver DR. Todtenkopf MS, et al. Among authors: turncliff rz. Addict Biol. 2009 Sep;14(4):408-18. doi: 10.1111/j.1369-1600.2009.00161.x. Epub 2009 Jun 1. Addict Biol. 2009. PMID: 19489752

10

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers.

Wilner KD, Tensfeldt TG, Baris B, Smolarek TA, Turncliff RZ, Colburn WA, Hansen RA. Wilner KD, et al. Among authors: turncliff rz. Br J Clin Pharmacol. 2000;49 Suppl 1(Suppl 1):15S-20S. doi: 10.1046/j.1365-2125.2000.00148.x. Br J Clin Pharmacol. 2000. PMID: 10771449 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results